Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Biogen Idec (NQ:BIIB)

193.53 -1.60 (-0.82%)
Streaming Delayed Price Updated: 10:25 AM EST, Feb 25, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Biogen Idec

< Previous 1 2 3 4 5 6 7 8 9
...
48 49 Next >
News headline image
3 Value Stocks Walking a Fine Line
The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer. However, the challenge lies in determining whether these cheap assets are genuinely undervalued... 
Via StockStory
News headline image
The 5 Most Interesting Analyst Questions From Biogen’s Q4 Earnings Call
Biogen’s fourth-quarter results were received positively by the market, as the company exceeded Wall Street’s revenue and non-GAAP profit expectations despite a year-over-year decline in sales.... 
Via StockStory
Topics Earnings
News headline image
1 Unpopular Stock That Deserves a Second Chance and 2 We Find Risky
When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fear their firms will lose out in other... 
Via StockStory
Biogen Stock To Pop Again? China Fast-Tracks At-Home Alzheimer’s Drug Leqembi ↗
Via Stocktwits
News headline image
BIIB Q4 Deep Dive: Pipeline Advances and New Product Launches Offset Legacy Headwinds
Biotech company Biogen (NASDAQ:BIIB) reported Q4 CY2025 results beating Wall Street’s revenue expectations, but sales fell by 7.1% year on year to $2.28 billion. Its non-GAAP profit of $1.99 per share... 
Via StockStory
News headline image
Why Biogen Stock Surged Almost 9% Higher on Friday ↗
It's obvious that the company has a good shot at returning to growth. 
Via The Motley Fool
What's going on in today's session: S&P500 movers ↗
Via Chartmill
News headline image
Biogen (BIIB) Q4 Earnings Preview: The "New Biogen" Emerges as Alzheimer's and Rare Disease Pipelines Take Center Stage
Biogen Inc. (NASDAQ: BIIB) reported its fourth-quarter and full-year 2025 financial results on February 6, 2026, signaling a definitive shift from a legacy company plagued by patent cliffs to a leaner,... 
Via MarketMinute
Topics Intellectual Property
News headline image
Biogen (BIIB) Q4 2025 Earnings Call Transcript ↗
Biogen (BIIB) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Biogen (BIIB) Deep Dive: Navigating the Pivot from MS Giant to Neuro-Innovation Powerhouse
As of February 6, 2026, Biogen Inc. (NASDAQ: BIIB) stands at a critical crossroads in its nearly 50-year history. Once the undisputed titan of the Multiple Sclerosis (MS) market, the Cambridge-based... 
Via Finterra
Topics Earnings Economy Intellectual Property
News headline image
Biogen’s (NASDAQ:BIIB) Q4 CY2025: Strong Sales
Biotech company Biogen (NASDAQ:BIIB) reported Q4 CY2025 results topping the market’s revenue expectations, but sales fell by 7.1% year on year to $2.28 billion. Its non-GAAP profit of $1.99 per share... 
Via StockStory
Topics Artificial Intelligence
News headline image
Biogen (BIIB) Reports Q4: Everything You Need To Know Ahead Of Earnings
Biotech company Biogen (NASDAQ:BIIB) will be reporting results this Friday before market open. Here’s what investors should know. 
Via StockStory
Topics Artificial Intelligence World Trade
Stay updated with the S&P500 stocks that are on the move in today's pre-market session. ↗
Via Chartmill
News headline image
1 Cash-Producing Stock to Keep an Eye On and 2 We Find Risky
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak... 
Via StockStory
News headline image
3 Biotech Stocks That Look Like “Sure-Fire” Winners in 2026 ↗
Via MarketBeat
Which S&P500 stocks are gapping on Wednesday? ↗
Via Chartmill
News headline image
3 Reasons to Sell BIIB and 1 Stock to Buy Instead
The past six months have been a windfall for Biogen’s shareholders. The company’s stock price has jumped 41.7%, setting a new 52-week high of $188.65 per share. This was partly thanks to its solid... 
Via StockStory
News headline image
The Trillion-Dollar Pharmacist: A 2026 Deep Dive into Eli Lilly (LLY)
As of January 9, 2026, Eli Lilly and Company (NYSE:LLY) has transitioned from a stalwart of the American pharmaceutical industry to a global financial phenomenon. Having recently crossed the historic... 
Via PredictStreet
Topics Earnings Economy Intellectual Property
News headline image
The Great Decoupling: How the AI Monetization Era Reshaped the Nasdaq in 2025
As of December 26, 2025, the Nasdaq Composite and Nasdaq-100 have reached historic milestones, closing out a year defined by the transition from artificial intelligence speculation to concrete... 
Via MarketMinute
Topics Artificial Intelligence Economy Stocks
News headline image
Biogen Inc. (NASDAQ:BIIB) Shows Strong Technical Setup for Potential Breakout ↗
Biogen (BIIB) shows a strong technical uptrend and a high-quality consolidation pattern, signaling a potential breakout opportunity for technical traders. 
Via Chartmill
News headline image
The Trillion-Dollar Pharma: A Deep Dive into Eli Lilly’s (LLY) Dominance in the Weight-Loss Era
As of December 25, 2025, the global pharmaceutical landscape has been fundamentally reshaped by a single entity: Eli Lilly and Company (NYSE: LLY). In a year defined by breakthrough medical treatments... 
Via PredictStreet
Topics Economy Government Intellectual Property
News headline image
Therapeutics Stocks Q3 In Review: Biogen (NASDAQ:BIIB) Vs Peers
As the Q3 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the therapeutics industry, including Biogen (NASDAQ:BIIB) and its peers. 
Via StockStory
Topics Artificial Intelligence
News headline image
Biogen (BIIB) Stock Trades Up, Here Is Why
Shares of biotech company Biogen (NASDAQ:BIIB) jumped 2.8% in the morning session after RBC Capital reiterated an "Outperform" rating and a $210 price target on the stock, naming it a top large-cap... 
Via StockStory
Topics Artificial Intelligence Economy
News headline image
$7 Trillion "Witching Hour": Unprecedented Derivatives Expiration Sparks Volatility on Wall Street
Today, December 19, 2025, marks the arrival of "Triple Witching" Friday, a quarterly phenomenon that has reached historic proportions this year. With an estimated $7.1 trillion in notional value of... 
Via MarketMinute
Topics Derivatives Economy Regulatory Compliance
News headline image
1 Nasdaq 100 Stock Worth Your Attention and 2 Facing Headwinds
The Nasdaq 100 (^NDX) is known for housing some of the most innovative and fastest-growing companies in the market. But not every stock in the index is a winner - some are struggling with slowing... 
Via StockStory
News headline image
3 Healthcare Stocks We Think Twice About
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Players catalyzing medical advancements have benefited from elevated demand, which has supported the... 
Via StockStory
Topics Stocks
News headline image
What's going on in today's session: S&P500 gap up and gap down stocks ↗
Let's take a look at the S&P500 stocks that are experiencing notable price gaps in today's session on Wednesday. Discover the gap up and gap down stocks in the S&P500 index. 
Via Chartmill
News headline image
1 S&P 500 Stock to Keep an Eye On and 2 Facing Headwinds
While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner. Some companies are past their prime, weighed down by poor execution, weak financials, or structural... 
Via StockStory
Topics Stocks
News headline image
Is Alnylam Pharmaceuticals a Millionaire Maker? ↗
This hot biotech stock could have a lot more room to run. 
Via The Motley Fool
News headline image
This Pharmaceutical Giant Fell by 10% After a Setback: Time to Sell the Stock? ↗
The issues are piling on for the healthcare leader, but this one is nowhere near insurmountable. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
48 49 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.